Methods of treating rbp4 related diseases with triazolopyridines
AssigneeBelite Bio, Inc
InventorsYu-Hsin Tom LIN, Cheng-Chi Irene WANG
Life of this patent
Estimating the term…
Abstract
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.
Claims20
A method of treating a metabolic disease or disorder in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer, or isomer thereof:
- wherein:
- each R1 is independently halogen, haloalkyl, or alkyl;
- R2 is —H, —OH, or halogen;
- p is 0, 1, 2, 3, 4, or 5;
- and
- A has the structure:
- wherein:
- α, β, χ, and δ are each independently absent or present, and when present each is a bond;
- X is N;
- Z1 is S, O, or N;
- Z2 is S, O, N, or NR3;
- R3 is H, C1-C4 alkyl, or oxetane;
- and
- B is a substituted or unsubstituted fused 5-, 6-, or 7-membered ring structure;
- and
- wherein the metabolic disease or disorder is type II diabetes or diabetic retinopathy.
A method of treating a metabolic disease or disorder in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a compound having the structure:
- or a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer, or isomer thereof;
- and
- wherein the metabolic disease or disorder is type II diabetes or diabetic retinopathy.
A method of treating a metabolic disease or disorder in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a compound having the structure:
- or a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer, or isomer thereof;
- and
- wherein the metabolic disease or disorder is type II diabetes or diabetic retinopathy.
Dependencies are inferred from the claim text.